February 2025—Adaptive Biotechnologies Corp. and NeoGenomics announced a multiyear exclusive strategic commercial collaboration that aims to advance minimal residual disease monitoring options for patients with select blood cancers.
Adaptive’s next-generation sequencing–based ClonoSeq is an FDA-cleared in vitro diagnostic test to detect MRD in lymphoid cancers. NeoGenomics’ Compass and Chart are personalized assessment services for complex blood cancers that offer a multimodal testing approach for patients. Under the terms of the agreement, Compass evaluations performed for patients with multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma can now include a ClonoSeq Clonality (ID) test, which identifies patient-specific DNA sequences at initial diagnosis and enables that patient for ClonoSeq MRD tracking. Subsequent Chart assessments can include ClonoSeq MRD testing throughout the continuum of care.
The companies expect to launch cross-promotional efforts later this year.
Adaptive Biotechnologies, 206-659-0067
NeoGenomics, 239-768-0600